Moderna testing key resistance level

Moderna Inc (MRNA) is testing a critical weekly resistance level at $159.93, marking a significant 9.83% increase as of Sep 17, 2026. Analysts have issued Strong Buy signals on both daily and weekly charts, but the stock faces a key hurdle at $160.71 to maintain its upward momentum. If this level is breached, a sharp sell-off could ensue due to an already overbought weekly RSI of 80.69.

Support is projected around the $145.62–$148.94 range, with a breach potentially leading to a deeper decline towards $141–$142. The current daily RSI stands at 66.65, still within a reasonable range but approaching overbought territory. The weekly RSI is stretched, while the weekly ADX at 35.83 confirms a strong ongoing trend rather than a stagnant range.

Moderna's recent success in Phase 3 personalized cancer-vaccine development with Merck is believed to have triggered this market reaction. To sustain this rally, the stock would need to hold above $152–$155, preserving the momentum structure. Conversely, a failure at $160.71, followed by a drop below $145.62, would indicate waning momentum.

The real question now is whether Moderna can transform the headline-driven surge into sustained gains above $160.71, effectively distinguishing continuation from consolidation.